Adolescent to Adult Patient-centered HIV Transition (ADAPT) Study

Sponsor
University of Maryland, Baltimore (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT02872805
Collaborator
(none)
298
1
2
36
8.3

Study Details

Study Description

Brief Summary

One of the distinct challenges faced by emerging adults with HIV is the transition of their care from their long-term pediatric HIV provider to treatment within an adult HIV program. The consequences of an unsuccessful transition can range from difficult to catastrophic. The Adolescent to Adult Patient-centered HIV Transition (ADAPT) Study is a prospective cohort trial of an innovative intervention targeting gaps in care that are major drivers of loss in the ART continuum of care cascade among adolescents and increasing missed opportunities to engage adolescents into care.

Condition or Disease Intervention/Treatment Phase
  • Other: PEPFAR Enhanced Standard of Care (PESCA)
  • Behavioral: Peer Transition Advocate (PTA)
N/A

Detailed Description

The specific aims of ADAPT are: 1. To inform strategies for transition services in resource-limited settings; 2. To examine the developmental, clinical, and other factors that predict a successful transition; and, 3. To gain fundamental insight on implementation barriers among African adolescents through the application of the ego-network defined social support that will inform targets for structured intervention. ADAPT will be conducted in central, southern, and northern Nigeria at selected PEPFAR sites supported by the Institute of Human Virology, Nigeria. To address Aim 1 the investigators will conduct six focus groups including: Adolescent patients, parents and health care providers. To address aim 2, the investigators will conduct a cluster randomized clinical trial. The two interventions are based on prior evidence-informed engagement strategies: 1) educational interventions and 2) interventions that use a peer transition advocate who prepares the adolescent and their parents for transition. The investigators will enroll 300 patients (150 patients in each arm). The sites will be assigned to either the intervention arm or a control arm. The primary outcome will be successful transition, keeping two follow-up appointments within a nine months period following transition. Secondary outcomes, as recommended by focus group participants will also be measured. To examine the potential role of social network components and characteristics of both egos and alters on primary outcomes, a Generalized Estimating Equation (GEE) approach will be used to explore the associations between primary outcomes and factors at the ego, alter, and network levels. The finding from this study will guide institution of best practices for transitioning adolescents in Nigeria and other countries lower and middle income countries with similar challenges and potential for high impact.

Study Design

Study Type:
Interventional
Actual Enrollment :
298 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Adolescent to Adult Patient-centered HIV Transition (ADAPT) Study
Actual Study Start Date :
Nov 1, 2019
Anticipated Primary Completion Date :
Oct 31, 2022
Anticipated Study Completion Date :
Oct 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: PEPFAR Enhanced Standard of Care (PESCA)

This arm reflects an enhanced standard of care comparison group for PEPFAR supported sites. We will provide standardized materials to be used by current clinical staff to help support whatever the site specific activities are related to transition from pediatric to adult medical care

Other: PEPFAR Enhanced Standard of Care (PESCA)
Standardized materials will be provided to PEPFAR supported clinical sites to assist clinic teams with supporting patients in the transition from pediatric to adult medical care
Other Names:
  • Enhanced Standard of Care
  • Experimental: Peer Transition Advocate (PTA)

    The PTAs will be present during patient clinic appointments to mentor and support participants in the development of independent health care behaviors. They will engage patients in role-plays to simulate appointments in adult practices. The PTAs will accompany patients during the transition process to the adult providers, to inform, support, and facilitate their successful transition to adult care. PTA duties, performed in the clinic and in the community, will include psychosocial support; facilitation of disclosure; adherence counseling, monitoring, and support; screening of patients for significant signs of illness and referral for care; and tracking and defaulter tracing of patients. PTA will support counseling and testing services for adolescents within the facilities. For those perinatally-infected, important care and support services include disclosure and stigma issues.

    Behavioral: Peer Transition Advocate (PTA)
    The PTAs will be present during patient clinic appointments to mentor and support participants in the development of independent health care behaviors. They will engage patients in role-plays to simulate appointments in adult practices. The PTAs will accompany patients during the transition process to the adult providers, to inform, support, and facilitate their successful transition to adult care. PTA duties, performed in the clinic and in the community, will include psychosocial support; facilitation of disclosure; adherence counseling, monitoring, and support; screening of patients for significant signs of illness and referral for care; and tracking and defaulter tracing of patients. PTA will support counseling and testing services for adolescents within the facilities. For those perinatally-infected, important care and support services include disclosure and stigma issues.

    Outcome Measures

    Primary Outcome Measures

    1. Successful transition [9 months after transition occurs]

      ADAPT focuses on a service primary outcome, successful transition, which is defined as two consecutive kept appointments at the designated adult clinic within 9 months of transition

    2. Viral load suppression [12 months after transition occurs]

      viral load (VL)<400 at 12 months post-transition

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    16 Years to 19 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • HIV infected patients between the ages of 16-19 years of age

    • Patients who have been in care at the study site facility for a minimum of 1 year

    • Patients who plan to transition their HIV care to one of the selected study sites

    • Patients who are able to provide informed consent

    Exclusion Criteria:
    • HIV infected patients who have significant cognitive impairments(e.g., Mental retardation)

    • Patients planning to transition their HIV care outside the selected study facilities

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Institute of Human Virology, Nigeria Abuja FCT Nigeria

    Sponsors and Collaborators

    • University of Maryland, Baltimore

    Investigators

    • Principal Investigator: Vicki J Tepper, Ph.D., University of Maryland School of Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Vicki Tepper, Associate Professor of Pediatrics, University of Maryland, Baltimore
    ClinicalTrials.gov Identifier:
    NCT02872805
    Other Study ID Numbers:
    • HP-00070099
    First Posted:
    Aug 19, 2016
    Last Update Posted:
    May 9, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of May 9, 2022